Baxter Investors Urged to Consider Leading Class Action Lawsuit Against Company

Introduction

Faruqi & Faruqi, LLP, a prominent national securities law firm, has issued a call to action for investors in Baxter International Inc., urging them to consider taking the lead in a federal securities class action lawsuit. The investigation stems from potential claims regarding Baxter's operations between February 23, 2022, and October 29, 2025, particularly accounting for serious defects in one of their key products, the Novum Large Volume Pump (LVP).

Background on Baxter International Inc.

Baxter International Inc. is a well-established healthcare company known for its innovative medical products, serving patients and healthcare providers across numerous jurisdictions. However, recent allegations have raised significant concerns about the safety and reliability of its products, particularly the Novum LVP, which is supposed to provide critical infusions in various medical settings.

Allegations Against Baxter

The core of the allegations against Baxter revolves around claims of misleading statements and omissions that could have impacted investors' financial decisions. The complaint asserts that Baxter executives failed to disclose serious systemic issues with the Novum LVP, which purportedly caused malfunctions such as underinfusion, overinfusion, or complete failure to deliver necessary fluids. These malfunctions exposed patients to dangerous risks, including serious injury and potential death. The firm alleges that Baxter was aware of these issues but failed to act adequately to ensure patient safety.

Moreover, it has been reported that Baxter's attempts to mitigate these malfunctions through customer alerts were not sufficient, leaving serious design flaws unaddressed. As a result, there was significant risk that healthcare providers would need to remove existing Novum LVPs from service altogether, which could adversely affect Baxter’s sales and market reputation.

Impact on Investors

On July 31, 2025, Baxter's announcement to voluntarily pause shipments and installations of the Novum LVP led to a drastic 22.4% drop in the company's stock price, closing at $21.76. This alarming downturn reflects the magnitude of the issue and its potential financial repercussions for investors. The adage “knowledge is power” rings true here; investors who were unaware of these underlying complications find themselves at risk of considerable financial loss.

Taking Action

Faruqi & Faruqi is encouraging any investor who acquired Baxter securities during the specified timeline to consider their legal rights and possible next steps. The class action lawsuit process allows plaintiffs, or lead plaintiffs appointed by the court, to represent the interests of all affected investors. Those interested can share their experiences and potentially bolster the case against the company.

Faruqi & Faruqi has emphasized that any member of the putative class can apply to serve as a lead plaintiff. However, the decision to take this step does not impact one's ability to receive any recovery from the lawsuit – members can choose to remain uninvolved in the litigation proceedings if they so desire.

Conclusion

With a deadline of December 15, 2025, looming for appointing a lead plaintiff in this class action, affected Baxter investors are urged to act swiftly. The firm is also open to communication from individuals with any additional knowledge about Baxter's practices, whether they be whistleblowers, former employees, or other stakeholders who may have insight into the situation. For those seeking more information about the class action lawsuit or wishing to discuss their options, Josh Wilson, an attorney at Faruqi & Faruqi, is available via direct lines provided in their notices.

In summary, Baxter International is at a crossroads, and the financial implications of their recent actions are unfolding. Investors are encouraged to stay informed and participate in ensuring that their voices are heard in this significant legal matter.